A psilocybin mushroom is not a single drug but a small chemical mixture. The headline compound, psilocybin, is a prodrug: the body strips off a phosphate group to make psilocin, and psilocin is what actually activates the serotonin 5-HT2A receptor. [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 [2] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 Alongside them sit minor tryptamines — baeocystin, norbaeocystin, aeruginascin — that are frequently invoked to explain why “whole mushrooms feel different”, yet their individual effects in humans are mostly unestablished; baeocystin alone, for example, failed to produce the standard psychedelic-like response in a controlled animal model. [3] Peer-reviewed Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin doi:10.1021/acs.jnatprod.9b01061 Knowing what the molecules are tells you how a mushroom could act, not how potent any given specimen is, and certainly not that microdosing works.
This is an evidence and biology review, not sourcing, foraging, or cultivation guidance. Psilocybin mushrooms are controlled in most jurisdictions, deadly lookalikes exist, and potency varies widely. Nothing here is instructions for finding, identifying, growing, storing, or dosing them.
Psilocybin is a delivery system for psilocin
The compound that gives these mushrooms their name does very little on its own. Psilocybin is a phosphorylated tryptamine, and the phosphate group is removed in the body — chiefly by enzymes in the gut and liver — to yield psilocin, the molecule that crosses into the brain and acts on serotonin receptors. [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 This is the textbook definition of a prodrug: an administered substance that is biologically inert until the body converts it into the active form. The detail of that conversion and how long psilocin lingers belongs to the pharmacokinetics article; here the point is simpler. When a mushroom is described by its “potency”, the meaningful figure is its combined psilocybin-and-psilocin content, because the psilocybin a person ingests will become psilocin regardless.
Psilocin’s activity comes from agonism at the serotonin 5-HT2A receptor, the same receptor that organizes the effects of other classic psychedelics. [2] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 That mechanism is covered in the 5-HT2A page. What matters for this cluster is that the active ingredient is a single, well-characterized molecule acting on a single, well-characterized receptor — which makes the rest of the mushroom’s chemistry, the minor alkaloids, the interesting and far less settled question.
| Compound | Role | Key property |
|---|---|---|
| Psilocybin | Prodrug present in the mushroom | More chemically stable; converted to psilocin in the body |
| Psilocin | Active form | Binds 5-HT2A; less stable, degrades more readily |
The minor alkaloids: real compounds, uncertain roles
Most psilocybin mushrooms contain more than just psilocybin and psilocin. Baeocystin, norbaeocystin, and aeruginascin are structurally related tryptamines that turn up, usually at lower concentrations, across many species. [4] Peer-reviewed Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids doi:10.3390/ijms232214068 Their presence is not in doubt. What is in doubt is what, if anything, they contribute to the human experience of eating a mushroom.
The honest framing cuts both ways. Appearing at a lower concentration is not a reason to dismiss a compound as irrelevant — biology is full of low-abundance molecules with real effects. But presence is also not proof of contribution: the fact that several alkaloids are in the tissue is not evidence that they meaningfully shape the human outcome. The correct category for the minor alkaloids is therefore uncertainty, held away from both dismissal and overclaim.
This is where careful chemistry punctures a popular story. When researchers synthesized these compounds and tested them, baeocystin on its own did not produce the head-twitch response that reliably tracks psychedelic-like 5-HT2A activation in mice — even though norpsilocin, a compound baeocystin can be converted into, was a potent receptor agonist. [3] Peer-reviewed Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin doi:10.1021/acs.jnatprod.9b01061 In other words, a minor alkaloid widely assumed to be psychoactive showed no such activity by itself in that assay, while its relevance hinges on a conversion step whose extent in humans is not well characterized. Aeruginascin’s story is similarly unsettled: it is often linked anecdotally to a particular quality of experience, but the rigorous pharmacology behind that claim is thin.
This is the place to resist the “entourage effect” overclaim. The entourage idea holds that the minor compounds, acting together, make a whole mushroom meaningfully different from an equivalent dose of pure psilocybin. It is a reasonable hypothesis and it may yet prove partly true. But it has not been demonstrated in controlled human studies, and a great deal of confident marketing language treats it as established fact. Plausibility is not demonstrated efficacy. For now, the responsible summary is that the major effects of any psilocybin mushroom are best explained by its psilocybin-and-psilocin content, with the minor alkaloids an open research question rather than a known multiplier.
| Claim | Status |
|---|---|
| Baeocystin, norbaeocystin, aeruginascin occur in many psilocybin mushrooms | Established |
| These compounds are structurally similar to psilocybin | Established |
| Each meaningfully alters the human experience on its own | Not established |
| A whole-mushroom “entourage effect” outperforms pure psilocybin | Not demonstrated |
Why this matters for interpreting a dose
If the major effect tracks psilocybin-plus-psilocin, then the central problem is still quantity, not chemistry: how much of those two compounds a given mushroom holds. That figure is the subject of potency variability and measuring potency. The minor-alkaloid uncertainty adds a second layer: even two mushrooms with identical psilocybin content could, in principle, differ in their minor-compound profile — but since we cannot yet say those minor compounds matter, this is a reason for humility about “full spectrum” claims, not a reason to believe them.
- Prodrug
- Psilocybin is biologically inactive until the body converts it to psilocin, the form that activates 5-HT2A. [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228
- Potency means two compounds
- A mushroom’s meaningful potency is its combined psilocybin-and-psilocin content, since the former becomes the latter. [2] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478
- Minor alkaloids, uncertain roles
- Baeocystin, norbaeocystin, and aeruginascin are present but their individual human effects are unestablished; baeocystin alone was inactive in a standard assay. [3] Peer-reviewed Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin doi:10.1021/acs.jnatprod.9b01061
- Entourage is a hypothesis
- A whole-mushroom advantage over pure psilocybin is plausible but not demonstrated in controlled human research. [4] Peer-reviewed Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids doi:10.3390/ijms232214068
Frequently asked questions
What is the difference between psilocybin and psilocin?
Psilocybin is the compound present in the mushroom; psilocin is what the body converts it into and the form that is actually pharmacologically active. In that sense psilocybin is a prodrug — an inactive carrier that becomes active after a chemical change. [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 Psilocin is what binds the serotonin 5-HT2A receptor and drives the effects, [2] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 while psilocybin’s main practical advantage is that it is more chemically stable than psilocin. When people talk about a mushroom’s “potency”, they usually mean its combined psilocybin-plus-psilocin content, because the psilocybin will become psilocin in the body anyway.
Do the minor alkaloids like baeocystin add to the effect?
This is genuinely uncertain, and it is a place where popular claims have run ahead of the evidence. Baeocystin, norbaeocystin, and aeruginascin are real tryptamines found in many psilocybin mushrooms, [4] Peer-reviewed Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids doi:10.3390/ijms232214068 but their individual contributions to the human experience are not well established. In a controlled study, baeocystin on its own did not produce the classic psychedelic-like response in an animal model, even though a related metabolite was a potent receptor agonist. [3] Peer-reviewed Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin doi:10.1021/acs.jnatprod.9b01061 So the idea of a strong “entourage effect” from these minor compounds is a hypothesis, not a demonstrated fact.
Is an 'entourage effect' from whole mushrooms proven?
No. The entourage idea — that whole-mushroom extracts produce richer or different effects than pure psilocybin because of the minor alkaloids and other compounds — is plausible and frequently asserted, but it has not been demonstrated in rigorous human research. Plausibility is not demonstrated efficacy. The honest position is that pure psilocybin is what has actually been studied in clinical trials, [2] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 and claims that the “full spectrum” of a mushroom is meaningfully better rest mostly on theory and anecdote at present.
Does this tell me how potent my mushrooms are?
No. Understanding which compounds are active does not tell you how much of them any particular mushroom contains, because that varies enormously and can only be established by laboratory analysis. [4] Peer-reviewed Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids doi:10.3390/ijms232214068 This article is about what the molecules are and do, not about quantifying or sourcing material. The variability problem is covered separately, and nothing here is dosing, sourcing, or cultivation guidance.